Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYDY CytoDyn	$0.29 +5.6%	$0.34	$0.10 ▼ $0.49	$356.69M	1.17	1.38 million shs	413,710 shs
KURA Kura Oncology	$5.91 +1.7%	$6.12	$5.41 ▼ $23.48	$507.33M	0.4	1.26 million shs	781,540 shs
MCRB Seres Therapeutics	$11.36 +4.6%	$8.27	$6.53 ▼ $30.60	$103.65M	2.75	134,471 shs	107,170 shs
MDGL Madrigal Pharmaceuticals	$298.49 -0.6%	$291.28	$200.63 ▼ $377.46	$6.64B	-1.05	359,776 shs	108,674 shs
MGNX MacroGenics	$1.44 +4.3%	$1.49	$0.99 ▼ $5.77	$92.11M	1.59	845,428 shs	699,979 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYDY CytoDyn	0.00%	+10.68%	-16.54%	+35.07%	+109.87%
KURA Kura Oncology	0.00%	+4.23%	-10.05%	+0.34%	-70.54%
MCRB Seres Therapeutics	0.00%	+24.78%	+56.40%	-11.29%	-19.10%
MDGL Madrigal Pharmaceuticals	0.00%	-0.75%	+8.90%	-5.06%	+9.87%
MGNX MacroGenics	0.00%	+21.01%	-0.69%	+35.85%	-65.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	4.556 of 5 stars	4.4	3.0	0.0	4.7	1.9	0.8	0.6
MCRB Seres Therapeutics	3.5634 of 5 stars	2.9	2.0	0.0	4.6	2.8	0.8	0.0
MDGL Madrigal Pharmaceuticals	4.0866 of 5 stars	3.4	0.0	0.0	4.6	2.2	3.3	0.6
MGNX MacroGenics	4.1248 of 5 stars	3.2	3.0	0.0	4.4	1.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYDY CytoDyn	0.00	N/A	N/A	N/A
KURA Kura Oncology	2.86	Moderate Buy	$24.50	314.55% Upside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	548.76% Upside
MDGL Madrigal Pharmaceuticals	2.89	Moderate Buy	$420.63	40.92% Upside
MGNX MacroGenics	2.40	Hold	$5.71	296.83% Upside

Current Analyst Ratings Breakdown

Latest MDGL, MGNX, MCRB, KURA, and CYDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/20/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$36.00
6/4/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
5/19/2025	KURA Kura Oncology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/14/2025	MGNX MacroGenics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$6.00 ➝ $5.00
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
5/2/2025	KURA Kura Oncology	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $11.00
5/2/2025	MDGL Madrigal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$441.00 ➝ $458.00
5/2/2025	MDGL Madrigal Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$422.00 ➝ $460.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYDY CytoDyn	N/A	N/A	N/A	N/A	($0.11) per share	N/A
KURA Kura Oncology	$67.99M	7.53	N/A	N/A	$5.32 per share	1.11
MCRB Seres Therapeutics	$126.32M	0.78	N/A	N/A	$1.61 per share	7.05
MDGL Madrigal Pharmaceuticals	$317.38M	20.88	N/A	N/A	$34.59 per share	8.63
MGNX MacroGenics	$149.96M	0.61	N/A	N/A	$1.85 per share	0.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYDY CytoDyn	-$49.84M	N/A	0.00	∞	N/A	N/A	N/A	-33.26%	8/14/2025 (Estimated)
KURA Kura Oncology	-$173.98M	-$2.10	N/A	N/A	N/A	N/A	-43.62%	-29.13%	8/6/2025 (Estimated)
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-41,084.76%	-55.87%	8/12/2025 (Estimated)
MDGL Madrigal Pharmaceuticals	-$465.89M	-$18.05	N/A	N/A	N/A	-123.38%	-50.54%	-37.19%	8/6/2025 (Estimated)
MGNX MacroGenics	-$66.97M	-$0.89	N/A	N/A	N/A	-36.23%	-59.84%	-23.45%	8/5/2025 (Estimated)

Latest MDGL, MGNX, MCRB, KURA, and CYDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	-$0.65	-$0.04	-$0.65	$9.59 million	$13.19 million
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A
5/1/2025	Q1 2025	KURA Kura Oncology	-$0.51	-$0.66	-$0.15	-$0.66	$39.08 million	$14.11 million
5/1/2025	Q1 2025	MDGL Madrigal Pharmaceuticals	-$3.62	-$3.32	+$0.30	-$3.32	$112.79 million	$137.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYDY CytoDyn	N/A	0.30	0.30
KURA Kura Oncology	0.02	8.07	8.07
MCRB Seres Therapeutics	N/A	2.11	2.11
MDGL Madrigal Pharmaceuticals	0.17	5.91	5.58
MGNX MacroGenics	N/A	3.28	3.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYDY CytoDyn	5.06%
KURA Kura Oncology	N/A
MCRB Seres Therapeutics	59.34%
MDGL Madrigal Pharmaceuticals	98.50%
MGNX MacroGenics	96.89%

Insider Ownership

Company	Insider Ownership
CYDY CytoDyn	0.54%
KURA Kura Oncology	6.40%
MCRB Seres Therapeutics	4.70%
MDGL Madrigal Pharmaceuticals	21.50%
MGNX MacroGenics	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYDY CytoDyn	20	1.25 billion	1.24 billion	Not Optionable
KURA Kura Oncology	130	86.58 million	81.03 million	Optionable
MCRB Seres Therapeutics	330	8.73 million	8.32 million	Optionable
MDGL Madrigal Pharmaceuticals	90	22.20 million	17.43 million	Optionable
MGNX MacroGenics	430	63.09 million	54.89 million	Optionable

MDGL, MGNX, MCRB, KURA, and CYDY Headlines

Recent News About These Companies

MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Rating of "Hold" from Analysts

July 4 at 2:57 AM | americanbankingnews.com

MacroGenics, Inc. (MGNX) Latest Stock News & Headlines - Yahoo Finance Canada

June 29, 2025 | ca.finance.yahoo.com

MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Hold" by Analysts

June 29, 2025 | marketbeat.com

MacroGenics (NASDAQ:MGNX) Cut to "Sell" at Wall Street Zen

June 29, 2025 | americanbankingnews.com

MacroGenics (NASDAQ:MGNX) Stock Rating Lowered by Wall Street Zen

June 27, 2025 | marketbeat.com

MacroGenics (NASDAQ:MGNX) Shares Pass Below Two Hundred Day Moving Average - Time to Sell?

June 18, 2025 | marketbeat.com

MacroGenics’ SWOT analysis: biotech firm’s stock faces pivotal year ahead

June 16, 2025 | investing.com

MacroGenics lands $70M 'infusion of cash' to advance clinical programs

June 13, 2025 | bizjournals.com

MacroGenics: Working On That Road To Recovery

June 11, 2025 | seekingalpha.com

MacroGenics Shares Rise on Royalty-Purchase Agreement

June 10, 2025 | marketwatch.com

MacroGenics Target of Unusually Large Options Trading (NASDAQ:MGNX)

June 10, 2025 | marketbeat.com

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement

June 10, 2025 | globenewswire.com

MacroGenics (NASDAQ:MGNX) Upgraded by Wall Street Zen to "Hold" Rating

June 7, 2025 | marketbeat.com

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

June 3, 2025 | globenewswire.com

Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies

May 23, 2025 | nasdaq.com

4 Medical Product Stocks to Watch From a Challenging Industry

May 21, 2025 | zacks.com

6MGNX : 4 Analysts Assess Macrogenics: What You Need To Know

May 20, 2025 | benzinga.com

MacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

May 16, 2025 | finanznachrichten.de

Earnings Release: Here's Why Analysts Cut Their MacroGenics, Inc. (NASDAQ:MGNX) Price Target To US$4.50

May 16, 2025 | finance.yahoo.com

MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates

May 13, 2025 | zacks.com

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

May 13, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDGL, MGNX, MCRB, KURA, and CYDY Company Descriptions

CytoDyn OTCMKTS:CYDY

$0.29 +0.02 (+5.56%)

As of 07/3/2025 12:59 PM Eastern

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Kura Oncology NASDAQ:KURA

$5.91 +0.10 (+1.72%)

Closing price 07/3/2025 03:35 PM Eastern

Extended Trading

$5.91 0.00 (0.00%)

As of 07/3/2025 04:58 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Seres Therapeutics NASDAQ:MCRB

$11.36 +0.50 (+4.56%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$11.94 +0.58 (+5.11%)

As of 07/3/2025 04:52 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Madrigal Pharmaceuticals NASDAQ:MDGL

$298.48 -1.67 (-0.55%)

Closing price 07/3/2025 03:39 PM Eastern

Extended Trading

$298.48 0.00 (0.00%)

As of 07/3/2025 04:09 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

MacroGenics NASDAQ:MGNX

$1.44 +0.06 (+4.35%)

As of 07/3/2025 03:37 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time